Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2 results about "Coagulation Factor IX" patented technology

Coagulation factor IX (461 aa, ~52 kDa) is encoded by the human F9 gene. This protein plays a role in the intrinsic pathway of blood coagulation through the mediation of proteolysis that converts factor X into an active protease.

A kit for coagulation factor Ⅸ detection and a preparation method thereof

The application belongs to the technical field of biological medicine, and particularly relates to a kit for coagulation factor IX detection and a preparation method thereof. The kit for coagulation factor IX detection comprises monoclonal antibody RFactor IX-1 coupled receptor microspheres, biotin-labeled monoclonal antibody RFactor IX-2, streptavidin-coupled donor microspheres, a standard, a standard buffer, and a 96-well white detection plate. The coagulation factor IX detection kit provided by the application has the advantages of simple operation, high precision, strong specificity, good stability and the like, can meet the needs of clinical efficient, accurate and stable detection of coagulation factor IX, and has a good clinical application prospect.
Owner:SHANDONG INST OF OCCUPATIONAL HEALTH & OCCUPATIONAL DISEASE PREVENTION +1

StRNA for treating hemophilia B and screening method thereof

This invention relates to a gene encoding coagulation factor IX. F9 This study investigates animal models of nonsense mutations, methods for screening hemophilia drugs using these models, and the application of the screened stRNAs in the preparation of hemophilia drugs. Based on an analysis of the probability of nonsense mutations in coagulation factor IX in hemophilia patients, the study verifies that stRNAs can read the coagulation factor IX encoding gene. F9 The function and efficiency of the premature termination codon (PTC) were investigated. Seven Arg-stRNAs were designed to target the coagulation factor IX R75* mutation, and readthrough efficiency was tested at the cellular level. A mouse model of the coagulation factor IX R75* mutation was constructed, and Arg-stRNA was delivered via AAV, restoring the expression of endogenous coagulation factor IX and reducing clotting time, demonstrating the effectiveness of stRNA in treating hemophilia B.
Owner:PEKING UNIV